A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

The primary objective of the study is to further evaluate the long-term safety and tolerability profiles of BG00002 (natalizumab) in Japanese participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objective of this study is to further evaluate the long-term efficacy profile of BG00002 in Japanese participants with RRMS.

本研究的主要目的是进一步评估BG00002（那他珠单抗，natalizumab）在复发缓解型多发性硬化（relapsing-remitting multiple sclerosis, RRMS）日本受试者中的长期安全性与耐受性特征。本研究的次要目的是进一步评估BG00002在复发缓解型多发性硬化（RRMS）日本受试者中的长期疗效特征。